[go: up one dir, main page]

WO2002018424A3 - Nouveaux acides nucleiques et polypeptides - Google Patents

Nouveaux acides nucleiques et polypeptides Download PDF

Info

Publication number
WO2002018424A3
WO2002018424A3 PCT/US2001/027093 US0127093W WO0218424A3 WO 2002018424 A3 WO2002018424 A3 WO 2002018424A3 US 0127093 W US0127093 W US 0127093W WO 0218424 A3 WO0218424 A3 WO 0218424A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
present
novel
polypeptide sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/027093
Other languages
English (en)
Other versions
WO2002018424A2 (fr
WO2002018424A9 (fr
Inventor
Y Tom Tang
Vinod Asundi
Ping Zhou
Aidong J Xue
Feiyan Ren
Jie Zhang
Jian-Rui Wang
Qing A Zhao
Dunrui Wang
Chenghua Liu
Radoje T Drmanac
Tom Wehrman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyseq Inc
Original Assignee
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc filed Critical Hyseq Inc
Priority to US10/363,616 priority Critical patent/US20040044181A1/en
Priority to AU2001292561A priority patent/AU2001292561A1/en
Priority to EP01972931A priority patent/EP1328636A2/fr
Priority to CA002421122A priority patent/CA2421122A1/fr
Publication of WO2002018424A2 publication Critical patent/WO2002018424A2/fr
Anticipated expiration legal-status Critical
Publication of WO2002018424A3 publication Critical patent/WO2002018424A3/fr
Publication of WO2002018424A9 publication Critical patent/WO2002018424A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux acides nucléiques, de nouvelles séquences polypeptidiques codées par ces acides nucléiques, et leurs utilisations.
PCT/US2001/027093 2000-09-01 2001-08-31 Nouveaux acides nucleiques et polypeptides Ceased WO2002018424A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/363,616 US20040044181A1 (en) 2001-08-31 2001-08-31 Novel nucleic acids and polypeptides
AU2001292561A AU2001292561A1 (en) 2000-09-01 2001-08-31 Nucleic acids and polypeptides
EP01972931A EP1328636A2 (fr) 2000-09-01 2001-08-31 Nouveaux acides nucleiques et polypeptides
CA002421122A CA2421122A1 (fr) 2000-09-01 2001-08-31 Nouveaux acides nucleiques et polypeptides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65493500A 2000-09-01 2000-09-01
US09/654,935 2000-09-01

Publications (3)

Publication Number Publication Date
WO2002018424A2 WO2002018424A2 (fr) 2002-03-07
WO2002018424A3 true WO2002018424A3 (fr) 2003-05-15
WO2002018424A9 WO2002018424A9 (fr) 2004-04-15

Family

ID=24626815

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027093 Ceased WO2002018424A2 (fr) 2000-09-01 2001-08-31 Nouveaux acides nucleiques et polypeptides

Country Status (4)

Country Link
EP (1) EP1328636A2 (fr)
AU (1) AU2001292561A1 (fr)
CA (1) CA2421122A1 (fr)
WO (1) WO2002018424A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018565A2 (fr) * 2000-08-30 2002-03-07 Bayer Aktiengesellschaft Regulation de l'enzyme humaine de type proteine phosphatase iic
GB0022670D0 (en) 2000-09-15 2000-11-01 Astrazeneca Ab Molecules
AU2002217134A1 (en) * 2000-12-26 2002-07-08 Bayer Aktiengesellschaft Regulation of human protein l-isoaspartate o-methyltransferase-like enzyme
US6913904B2 (en) * 2001-03-27 2005-07-05 Applera Corporation Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
AU2002318112B2 (en) 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1661998A3 (fr) * 2001-06-04 2006-12-06 Curagen Corporation Polypeptides antigéniques, anticorps s'y liant, acides nucléiques codant pour les antigènes, et méthodes pour leur utilisation
AU2002316631A1 (en) * 2001-07-12 2003-01-29 Exelixis, Inc. Ube2s as modifiers of the p21 pathway and methods of use
WO2003042362A2 (fr) * 2001-11-09 2003-05-22 Dana-Farber Cancer Institute, Inc. Pgc-1$g(b), un nouvel homologue du pgc-1 et leurs utilisations
WO2004038372A2 (fr) * 2002-10-23 2004-05-06 Exelixis, Inc. Cdkl1 utilise en tant que modificateur de la morphogenese de branchement, et procedes d'utilisation du cdkl1
GB0328928D0 (en) * 2003-12-12 2004-01-14 Cancer Rec Tech Ltd Materials and methods relating to cell cycle control
WO2006005584A1 (fr) * 2004-07-12 2006-01-19 Geneprot Inc. Espece de polypeptides utile pour le traitement de troubles neurologiques
WO2006092209A1 (fr) * 2005-03-02 2006-09-08 Galapagos Nv Nouvelles cibles et composes utilises pour traiter un trouble cardio-vasculaire, une dyslipidemie et une atherosclerose et procedes pour identifier de tels composes
ES2625259T3 (es) 2006-08-29 2017-07-19 Oxford Biotherapeutics Ltd Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
PL2403878T3 (pl) 2009-03-05 2017-12-29 E. R. Squibb & Sons, L.L.C. W pełni ludzkie przeciwciała specyficzne dla CADM1
EP3450979A3 (fr) 2010-03-17 2019-04-24 The Regents of The University of Michigan Utilisation d'épitopes de phage à des fins de profilage de la réponse immunitaire
RS62529B1 (sr) 2013-07-11 2021-11-30 Modernatx Inc Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
CA3178965A1 (fr) 2020-05-15 2021-11-18 Christian COBAUGH Arn messager codant pour cas9 destine a etre utilise dans des systemes d'edition du genome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053312A1 (fr) * 1999-12-23 2001-07-26 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 18 July 1996 (1996-07-18), HILLIER L. ET AL.: "zh48g06.r1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:415354 5' similar to PIR:S23352 S23352 gene unc-93 protein 1 - Caenorhabditis elegans [1] ;, mRNA sequence.", XP002214455, retrieved from EBI Database accession no. W92071 *
DATABASE EMBL [online] 19 January 1998 (1998-01-19), PHILIPPS, S:: "Human DNA sequence from clone 366N23 on chromosome 6q27. Contains two genes similar to consecutive parts of the C. elegans UNC-93 (protein 1, C46F11.1) gene, a KIAA0173 and Tubulin-Tyrosine Ligase LIKE gene, a Mitotic Feedback...", XP002214453, retrieved from EBI Database accession no. AL021331 *
DATABASE SWALL [online] 1 November 1998 (1998-11-01), PHILLIPS, S.: "DJ366N23.1 (Putative C. elegans UNC-93 (Protein 1, C46F11.1) like protein).", XP002214454, retrieved from EBI Database accession no. O75651 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US8617547B2 (en) 2004-06-09 2013-12-31 The Regents Of The University Of Michigan Methods and compositions for diagnosing prostate cancer
US9267133B2 (en) 2004-06-09 2016-02-23 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease

Also Published As

Publication number Publication date
CA2421122A1 (fr) 2002-03-07
EP1328636A2 (fr) 2003-07-23
WO2002018424A2 (fr) 2002-03-07
AU2001292561A1 (en) 2002-03-13
WO2002018424A9 (fr) 2004-04-15

Similar Documents

Publication Publication Date Title
WO2001075067A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003054152A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003025148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002070539A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003023013A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002081731A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2004009834A3 (fr) Nouveaux acides nucleiques et polypeptides secretes
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003029271A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2003080795A3 (fr) Nouveaux acides nucléiques et polypeptides sécrétés
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001002571A3 (fr) Nouvel antagoniste du recepteur d'interleukin-1 et ses utilisations
WO2002044340A3 (fr) Nouveaux acides nucleiques et polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2421122

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001972931

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10363616

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001972931

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 282, 283, CLAIMS, ADDED; DUE TO A SCANNING ERROR DURING THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION, REPLACE ALL PAGES (INCLUDING FRONT PAGE) BY CORRECT PAGES (286 PAGES)

WWW Wipo information: withdrawn in national office

Ref document number: 2001972931

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP